Leerink Partnrs Reduces Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Kura Oncology in a research note issued on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn $0.15 per share for the quarter, down from their prior forecast of $0.16. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology's Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

Other equities research analysts have also issued research reports about the stock. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a report on Tuesday, April 29th. Barclays lowered their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. StockNews.com downgraded Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Stock Performance

Kura Oncology stock traded up $0.14 during trading hours on Monday, hitting $6.38. The stock had a trading volume of 1,236,324 shares, compared to its average volume of 1,183,276. The company has a 50-day moving average of $6.37 and a two-hundred day moving average of $8.63. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $552.35 million, a PE ratio of -2.70 and a beta of 0.50. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million.

Institutional Trading of Kura Oncology

Large investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its position in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after purchasing an additional 3,061 shares in the last quarter. State of Wyoming acquired a new position in shares of Kura Oncology during the first quarter worth approximately $48,000. Harbor Advisors LLC acquired a new position in shares of Kura Oncology during the fourth quarter worth approximately $87,000. Pallas Capital Advisors LLC acquired a new position in shares of Kura Oncology during the first quarter worth approximately $66,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology during the fourth quarter worth approximately $90,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.